Compare Amgen, Inc. (AMGN) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Ralph Lauren Corp — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Ralph Lauren Corp trades at $393.26 (market cap $23.50B). The key difference: Amgen, Inc. is far larger — about 8.3× Ralph Lauren Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RL | |
|---|---|---|
Market Cap | $196.12B | $23.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $414.25 |
52-Week Low | $271.18 | $283.34 |
Enterprise Value | $241.41B | $24.45B |
Dividend Yield | 2.77% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Ralph Lauren (RL) trades at $394.9, up 1.89% today, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows strong fundamentals with a 10.49% net income margin and 34.66% ROE, though technical indicators signal near-term bearish pressure. Recent news highlights brand momentum in Asia and digital expansion under its Next Great Chapter plan, supporting growth prospects.
The outlook is positive given consistent earnings beats and analyst consensus favoring a buy rating with a $446.25 price target, implying 13% upside. Key risks include premium valuation multiples and macroeconomic headwinds affecting consumer discretionary spending, but strong cash flow and margin expansion provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
